menu
    • menu

    Company profile for Accord BioPharma

    NEW Drugs in Dev: 6
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patient's perspective and develop high-quality therapies that impact patient's lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Accord BioPharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1009 Slater Rd Ste 210B Durham, NC, 27703-8446
    Telephone
    Telephone
    +1-919-941-7878
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.accordbiopharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bio-Thera Golimumab Biosimilars Gain First FDA Approval
    Bio-Thera Golimumab Biosimilars Gain First FDA Approval

    18 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bio-thera-solutions-golimumab-biosimilars-receive-fda-approval-as-first-biosimilars-to-simponi-and-simponi-aria-accord-biopharma-to-commercialize-immgolis-golimumab-sldi-and-immgolis-intri-golimumab-sldi-in-the-united-st-302774570.html

    PR NEWSWIRE
    18 May 2026
    Share Share
    Accord Biopharma’s Biologics Ennumo Receives Approval in US
    Accord Biopharma’s Biologics Ennumo Receives Approval in US

    07 May 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761147

    FDA
    07 May 2026
    Share Share
    FDA Approves FILKRI, Accord BioPharma's Biosimilar to NEUPOGEN
    FDA Approves FILKRI, Accord BioPharma's Biosimilar to NEUPOGEN

    17 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-approves-filkri-filgrastim-laha-accord-biopharmas-biosimilar-to-neupogen-filgrastim-302689073.html

    PR NEWSWIRE
    17 Feb 2026
    Share Share
    Accord Biopharma’s Biologics Filkri Receives Approval in US
    Accord Biopharma’s Biologics Filkri Receives Approval in US

    15 Jan 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761027

    FDA
    15 Jan 2026
    Share Share
    Accord Biopharma's Hercessi Receives Preferred Status
    Accord Biopharma's Hercessi Receives Preferred Status

    05 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/accord-biopharmas-hercessi-trastuzumab-strf-gains-preferred-status-on-express-scripts-national-commercial-formularies-302646483.html

    PR NEWSWIRE
    05 Jan 2026
    Share Share
    Accord Biopharma Adds IMULDOSA To Express Scripts Formularies
    Accord Biopharma Adds IMULDOSA To Express Scripts Formularies

    01 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/accord-biopharmas-imuldosa-ustekinumab-srlf-added-to-express-scripts-national-commercial-formularies-302628636.html

    PR NEWSWIRE
    01 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search